Remsima® SC provides an alternative treatment option for patients with CD, UC, AS, PsA, PsO, and RA. 1
Availability of infliximab dual formulation as IV and SC provides a treatment that can be tailored to the individual needs of your patients.2
Remsima® SC offers comparable efficacy with stable potency and immunogenicity benefits to infliximab IV administration.3
1. Remsima® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/Remsima®-epar-product-information_en.pdf Accessed 4 Sep 2020.
2. Jin, Jing-Fen et al. “The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. ” Patient preference and adherence vol. 9 923-42. 2 Jul. 2015, doi:10.2147/PPA.S87271
3. Ben-Horin S et al. A novel subcutaneous infliximab (CT-P13): 1-year results including a switch from intravenous infliximab (CT-P13) in patients with active Crohn’s Disease and Ulcerative Colitis. OP24. Presented at ECCO 2020, 12–15 February, Vienna.
AS, ankylosing spondylitis; CD, Crohn's disease; EMA, European Medicines Agency; IV, intravenous; PsA, psoriatic arthritis; PsO, plaque psoriasis; RA, rheumatoid arthritis; SC, subcutaneous; UC, ulcerative colitis
The link you have selected will take you to a third-party website. It is not under the review or control of Celltrion Healthcare and the company does not review or control the contents. The company does not endorse the content, its accuracy or any practices and standards contained in the website.
Please confirm if you wish to follow the link.